Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Oral Communications

The curious case of growth hormone

ea0056oc13.1 | The curious case of growth hormone | ECE2018

Postoperative use of somatostatin analogs and mortality in patients with acromegaly

Postma Mark R , Wolters Thalijn LC , van den Berg Gerrit , van Herwaarden Antonius E , Kobold Anneke C Muller , Sluiter Wim J , Wagenmakers Margreet A , van den Bergh Alfons CM , Wolffenbuttel Bruce HR , Hermus Ad RMM , Netea-Maier Romana T , van Beek Andre P

Objective: To assess the effect of somatostatin analogs (SSTA) on mortality in relation to metabolic control of acromegaly after pituitary surgery.Design: A retrospective study in two large tertiary referral centers in The Netherlands.Patients and methods: Three hundred and nineteen patients with acromegaly in whom pituitary surgery was performed as primary therapy between January 1980 and July 2017 were included (total follow-up: ...

ea0056oc13.2 | The curious case of growth hormone | ECE2018

Time trends of mortality in patients with GH secreting and non-functioning pituitary adenoma

Galoiu Simona , Silea Simona , Baciu Ionela , Trifanescu Raluca Alexandra , Niculescu Dan , Capatina Cristina , Radian Serban , Dumitrascu Anda , Caragheorgheopol Andra , Poiana Catalina

Background and aims: Patients with GH secreting or nonfunctioning pituitary adenoma (NFPA) have high mortality ratios, despite enhancement of the old therapies. The aim of the study is to analyze the relationship between mortality and risk factors, including therapy, in patients with acromegaly (ACM) and NFPA evaluated in the last 16 years.Methods: We evaluated retrospectively 749 patients with pituitary adenoma (435F/314M), 386 with ACM and 363 with NFP...

ea0056oc13.3 | The curious case of growth hormone | ECE2018

Molecular profiling for assistance to pharmacological treatment of acromegaly

Puig-Domingo Manuel , Gil Joan , Sampedro Miguel , Webb Susan M , Serra Guillermo , Salinas Isabel , Blanco Alberto , Marques-Pamies Montse , Pico Antonio , Garcia-Martinez Araceli , Blanco Concepcion , Del Pozo Carlos , Obiols Gabriel , Alvarez-Escola Cristina , Camara Rosa , Fajardo Carmen , Luque Raul , Castano Justo , Robledo Mercedes , Jorda Mireia , Bernabeu Ignacio , Marazuela Monica

Pharmacologic treatment of acromegaly is currently based upon assay-error strategy in which first generation somatostatin analogs (SSA) is the first-line treatment. However, about 50% of patients do no respond adequately to SSA. We aimed to evaluate the potential usefulness of including studies of molecular markers identifying poor response to SSA for prescription of pharmacologic treatment in acromegalic patients in which SSA was prescribed before surgical therapy.<p clas...

ea0056oc13.4 | The curious case of growth hormone | ECE2018

Effects of pegvisomant on glucose metabolism in acromegaly: A meta-analysis of prospective interventional studies

Feola Tiziana , Cozzolino Alessia , Puliani Giulia , Sbardella Emilia , Gianfrilli Daniele , Hasenmajer Valeria , Simonelli Ilaria , Pasqualetti Patrizio , Lenzi Andrea , Isidori Andrea M.

Introduction: Glucose metabolism impairment is a common complication of acromegaly. Pegvisomant (PEG) is used as second-line medical treatment in acromegaly. Data from literature suggest a positive effect of PEG on glucose metabolism but a meta-analysis has never been performed.Aim: To address the following questions: i) does PEG affect glucose metabolism? ii) does the effect correlate with disease control?Methods: We performed a m...

ea0056oc13.5 | The curious case of growth hormone | ECE2018

Growth hormone acts in AgRP neurons to control energy expenditure during food restriction and promotes counter-regulatory responses to hypoglycemia via the ventromedial hypothalamus

Furigo Isadora C , Teixeira Pryscila DS , Souza Gabriel O , List Eduard , Kopchick John , Donato Jose

Growth hormone (GH) responsive cells are extensively distributed in central nervous system, including in neurons of the arcuate (ARH) and ventromedial nucleus (VMH) of hypothalamus, areas that control food intake, energy expenditure and blood glucose. During metabolic stresses, such as food restriction and hypoglycemia, GH secretion is stimulated and may be important to maintain survival. In the present study, we first verified that an acute GH injection stimulates food intake...